Johanna Mylet - Dec 21, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Financial Officer
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Dec 21, 2021
Transactions value $
$9,061
Form type
4
Date filed
12/22/2021, 03:53 PM
Previous filing
Nov 2, 2021
Next filing
Mar 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $3.07K +2.62K +9.17% $1.17 31.1K Dec 21, 2021 Direct
transaction PSTX Common Stock Options Exercise $5.99K +3.1K +9.96% $1.93 34.2K Dec 21, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to Buy) Options Exercise $0 -2.62K -100% $0.00* 0 Dec 21, 2021 Common Stock 2.62K $1.17 Direct F1
transaction PSTX Stock Option (Right to Buy) Options Exercise $0 -3.1K -44.82% $0.00 3.82K Dec 21, 2021 Common Stock 3.1K $1.93 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 12.5% of the shares shares subject to the stock option vested and became exercisable on August 6, 2018, and the remaining shares vest in 42 equal monthly installments thereafter.